Breaking News Instant updates and real-time market news.

PFE

Pfizer

$44.09

-0.28 (-0.63%)

, LLY

Eli Lilly

$110.41

-1.66 (-1.48%)

18:42
10/23/18
10/23
18:42
10/23/18
18:42

Pfizer, Eli Lilly: Phase 3 study of tanezumab met all three co-primary endpoints

Pfizer (PFE) and Eli Lilly and Company (LLY) announced complete results from a Phase 3 study evaluating the efficacy and safety of subcutaneous administration of tanezumab, an investigational humanized monoclonal antibody, in patients with osteoarthritis pain treated for 16 weeks. The study met all three co-primary efficacy endpoints, demonstrating that among patients with moderate-to-severe OA pain of the knee or hip, both dosing regimens of tanezumab were associated with a statistically significant improvement in pain, physical function and patient's global assessment of their OA, compared to placebo. These data were presented during a late-breaking oral session at the 2018 American College of Rheumatology/Association of Rheumatology for Health Professionals Annual Meeting in Chicago. "The results demonstrated by tanezumab in this study are particularly meaningful, given that patients had moderate-to-severe pain and were unable to achieve adequate pain relief with other treatment options, including opioids and NSAIDs," said Ken Verburg, tanezumab development team leader, Pfizer Global Product Development. "Our goal is to be able to offer tanezumab as a potential non-opioid treatment option for these patients suffering from osteoarthritis pain."

PFE

Pfizer

$44.09

-0.28 (-0.63%)

LLY

Eli Lilly

$110.41

-1.66 (-1.48%)

  • 30

    Oct

  • 06

    Nov

  • 07

    Nov

  • 12

    Nov

PFE Pfizer
$44.09

-0.28 (-0.63%)

10/02/18
PIPR
10/02/18
NO CHANGE
Target $100
PIPR
Neutral
AbbVie scripts for Humira relatively weak in Q3, says Piper Jaffray
Piper Jaffray analyst Christopher Raymond says new survey data from dermatologists and gastroenterologists indicate AbbVie's (ABBV) Humira is losing share faster in psoriasis and inflammatory bowel disease than in rheumatoid arthritis. In that management has called out psoriasis as a key driver of growth, the survey feedback may help explain Humira's relatively weak script trends for Q3, Raymond tells investors in a research note. The analyst believes dermatologists are embracing newer biologics such as Johnson & Johnson's (JNJ) Tremfya while gastroenterologists favor Takeda's Entyvio and increasingly Pfizer's (PFE) Xeljanz. Raymond remains cautious on shares of AbbVie ahead of European biosimilar erosion he expects to start this month. He keeps a Neutral rating on the stock with a $100 price target.
10/08/18
GSCO
10/08/18
NO CHANGE
Target $36
GSCO
Sell
Ionis' Tegsedi to face commercial headwinds, says Goldman Sachs
After the FDA approved Ionis (IONS) and affiliate Akcea Therapeutics' (AKCA) Tegsedi for adult polyneuropathy of hereditary transthyretin-mediated amyloidosis, but with a black box warning, Goldman Sachs analyst Salveen Richter said he believes the drug faces commercial headwinds. He cites the underlying safety profile and requirement for consistent monitoring as well as the recent launch of Alnylam's (ALNY) Onpattro and expected launch of Pfizer's (PFE) tafamidis in the first half of 2019. Richter keeps a Sell rating on Ionis shares with a price target of $36.
10/16/18
WELS
10/16/18
NO CHANGE
WELS
Drug price in ads not impactful, may cause confusion, says Wells Fargo
Wells Fargo analyst David Maris acknowledges that the U.S. Department of Health and Human Services' proposal to include drug prices in advertisements has a "noble goal" of making drugs more affordable and keeping patients well informed. However, given how different list prices are relative to out of pocket costs, "one must ask if this is increasing transparency or likely going to lead to more confusion," he contends. The analyst also believes that the unintended consequence could be worse care, while noting that the drug price information will likely fall into the category of the side effect information in drug ads currently, tuned out by many and will have no material impact. While he supports the idea of increased transparency, Maris wonders whether the potential benefit is not outweighed by the potential negative for the most vulnerable. Publicly traded companies in the space include AstraZeneca (AZN), Bristol-Myers (BMY), Eli Lilly (LLY), GlaxoSmithKline (GSK), Johnson & Johnson (JNJ), Merck (MRK), Novartis (NVS), Pfizer (PFE), Roche (RHHBY) and Sanofi (SNY).
10/23/18
WOLF
10/23/18
INITIATION
Target $46
WOLF
Peer Perform
Pfizer reinitiated with a Peer Perform at Wolfe Research
Wolfe Research analyst Time Anderson reinitiated Pfizer with a Peer Perform and $46 price target.
LLY Eli Lilly
$110.41

-1.66 (-1.48%)

10/15/18
FBCO
10/15/18
INITIATION
Target $36
FBCO
Neutral
Elanco initiated with a Neutral at Credit Suisse
Credit Suisse analyst Erin Wright started Elanco (ELAN) with a Neutral rating and $36 price target. As the fourth-largest animal health therapeutics company, Elanco is highly levered to robust industry fundamentals across livestock and companion animal markets, and earnings growth should accelerate on dedicated innovation efforts and dramatically improving cost structure as a more nimble unencumbered entity, unchained to Eli Lilly (LLY), its large pharmaceutical parent, she contends.
10/22/18
HCWC
10/22/18
NO CHANGE
Target $54
HCWC
Neutral
Roche data should concern Nektar bulls, says H.C. Wainwright
H.C. Wainwright analyst Debjit Chattopadhyay believes Roche's (RHHBY) preliminary data of RO6875281, a fibroblast activation protein targeted interleukin-2 variant, should concern the bulls of Nektar Therapeutics (NKTR). The 11% and 20% overall response rate for single agent RO6875281 in squamous cell head and neck cancer and melanoma is compelling, Chattopadhyay tells investors in a research note. Nektar's NKTR-214 had no monotherapy activity, and the early promise in combination with Opdivo "has faded potentially due to its limited PK profile," the analyst adds. In addition, Chattopadhyay believes the monotherapy activity with pegilodecakin, a pegylated IL-10 being developed by Eli Lily (LLY), further complicates the competitive landscape for NKTR-214. He believes the second generation of "not alpha" IL-2, which is poised to enter the clinic during 2019, could further "upend" NKTR-214 and might compel Nektar's partner Bristol-Myers Squibb (BMY) to "re-evaluate the aggressive development strategy that was outlined earlier this year." The analyst keeps a Neutral rating on Nektar with a $54 price target.
10/23/18
WOLF
10/23/18
INITIATION
Target $119
WOLF
Peer Perform
Eli Lilly reinitiated with a Peer Perform at Wolfe Research
Wolfe Research analyst Time Anderson reinitiated Eli Lilly with a Peer Perform and $119 price target.

TODAY'S FREE FLY STORIES

OESX

Orion Energy

$0.91

0.017 (1.90%)

14:52
03/25/19
03/25
14:52
03/25/19
14:52
Hot Stocks
Orion CEO sees 'great possibilities' of migrating customers to LED »

In an exclusive interview…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Mar

KMX

CarMax

$61.69

0.73 (1.20%)

14:50
03/25/19
03/25
14:50
03/25/19
14:50
Options
Carmax option volume is 3X daily average and puts lead calls 5:1 »

Carmax option volume is…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Mar

  • 25

    Jun

RHT

Red Hat

$181.72

0.09 (0.05%)

14:49
03/25/19
03/25
14:49
03/25/19
14:49
Options
Red Hat options imply 2.8% move in share price post-earnings, below median historical move »

Pre-earnings options…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ANGI

Angi Homeservices

$16.01

-0.52 (-3.15%)

14:45
03/25/19
03/25
14:45
03/25/19
14:45
Conference/Events
Angi Homeservices management to meet with Wedbush »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Mar

  • 26

    Mar

  • 27

    Mar

  • 27

    Mar

AAPL

Apple

$187.70

-3.41 (-1.78%)

14:43
03/25/19
03/25
14:43
03/25/19
14:43
Hot Stocks
Apple announces Apple TV+ service with exclusive original content »

Apple announced original…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Mar

  • 03

    Jun

PCG

PG&E

$18.25

-0.9 (-4.70%)

14:40
03/25/19
03/25
14:40
03/25/19
14:40
Options
Big option prints in PG&E as shares drop 5.1% »

Big option prints in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AAPL

Apple

$187.55

-3.56 (-1.86%)

14:38
03/25/19
03/25
14:38
03/25/19
14:38
Hot Stocks
Breaking Hot Stocks news story on Apple »

Apple TV+ pricing details…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Mar

  • 03

    Jun

AAPL

Apple

$187.33

-3.78 (-1.98%)

14:38
03/25/19
03/25
14:38
03/25/19
14:38
Hot Stocks
Breaking Hot Stocks news story on Apple »

Apple says TV+ will…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Mar

  • 03

    Jun

TIER

Tier REIT

$27.18

1.67 (6.55%)

, CUZ

Cousins Properties

$9.26

-0.62 (-6.28%)

14:33
03/25/19
03/25
14:33
03/25/19
14:33
Downgrade
Tier REIT, Cousins Properties rating change  »

Tier REIT downgraded to…

TIER

Tier REIT

$27.18

1.67 (6.55%)

CUZ

Cousins Properties

$9.26

-0.62 (-6.28%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Mar

  • 25

    Mar

  • 23

    Apr

UUUU

Energy Fuels

$3.19

0.04 (1.27%)

14:30
03/25/19
03/25
14:30
03/25/19
14:30
Options
Trader scoops up nearly 2K lotto ticket calls in Energy Fuels »

Trader scoops up nearly…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PLD

Prologis

$71.09

0.03 (0.04%)

14:28
03/25/19
03/25
14:28
03/25/19
14:28
Hot Stocks
Prologis CLO sells over 16,000 common shares »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Apr

CRSP

Crispr Therapeutics

$33.86

-1.73 (-4.86%)

14:28
03/25/19
03/25
14:28
03/25/19
14:28
Conference/Events
Crispr Therapeutics management to meet with Needham »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Apr

  • 08

    Apr

IONS

Ionis Pharmaceuticals

$78.76

-0.24 (-0.30%)

14:27
03/25/19
03/25
14:27
03/25/19
14:27
Conference/Events
Ionis Pharmaceuticals management to meet with Needham »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Apr

OESX

Orion Energy

$0.91

0.017 (1.90%)

14:25
03/25/19
03/25
14:25
03/25/19
14:25
Hot Stocks
Orion's Altschaefl says new products coming in April, May »

In an exclusive interview…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Mar

AXSM

Axsome Therapeutics

$15.30

2.3 (17.69%)

14:25
03/25/19
03/25
14:25
03/25/19
14:25
Options
Axsome Therapeutics call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

WDAY

Workday

$189.95

-1.05 (-0.55%)

14:21
03/25/19
03/25
14:21
03/25/19
14:21
Hot Stocks
Workday says CIO McKenzie departing in April, Rhodes joining as new CIO »

In a blog post, Workday…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jun

$NSD

NASDAQ Market Internals

$0.00

(0.00%)

14:17
03/25/19
03/25
14:17
03/25/19
14:17
Technical Analysis
NASDAQ market internals summary »

Volume is above average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

$0.00

(0.00%)

14:16
03/25/19
03/25
14:16
03/25/19
14:16
Technical Analysis
NYSE market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BLK

BlackRock

$415.08

-1.92 (-0.46%)

, APO

Apollo Global

$27.93

-0.07 (-0.25%)

14:10
03/25/19
03/25
14:10
03/25/19
14:10
Periodicals
BlackRock, Varde to make rival offers for Banca Carige, Reuters reports »

Varde Partners and…

BLK

BlackRock

$415.08

-1.92 (-0.46%)

APO

Apollo Global

$27.93

-0.07 (-0.25%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Oct

F

Ford

$8.53

0.005 (0.06%)

14:10
03/25/19
03/25
14:10
03/25/19
14:10
Options
Ford puts lead calls 6:1 »

Ford puts lead calls 6:1.…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

  • 24

    Jul

  • 23

    Oct

ASND

Ascendis Pharma

$115.50

-3.71 (-3.11%)

14:07
03/25/19
03/25
14:07
03/25/19
14:07
Hot Stocks
Ascendis Pharma announces results of study of hypoparathyroidism at ENDO 2019 »

Ascendis Pharma announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AAPL

Apple

$188.31

-2.8 (-1.47%)

14:07
03/25/19
03/25
14:07
03/25/19
14:07
Hot Stocks
Breaking Hot Stocks news story on Apple »

Apple says Apple TV+ will…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Mar

  • 03

    Jun

IP

International Paper

$44.43

0.03 (0.07%)

14:05
03/25/19
03/25
14:05
03/25/19
14:05
Options
International Paper call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AAPL

Apple

$188.74

-2.37 (-1.24%)

14:05
03/25/19
03/25
14:05
03/25/19
14:05
Hot Stocks
Breaking Hot Stocks news story on Apple »

Apple CEO Tim Cook…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Mar

  • 03

    Jun

14:05
03/25/19
03/25
14:05
03/25/19
14:05
General news
Treasury Action: the $40 B 2-year note sale Tuesday »

Treasury Action: the $40…

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.